Key facts
| Price (PPV) | 85 MAD |
|---|---|
| Dispensing status | Schedule A — prescription only |
| Composition (DCI) | irbesartanhydrochlorotiazide |
| Class | Agents acting on the renin-angiotensin system |
| ATC code | C09DA04 |
| Manufacturer | AFRIC-PHAR |
| Presentation | Boite de 14 |
| Nature | Médicament |
| Hospital price | 53.10 MAD |
| Data collected on | 9/8/2026 |
Find an open pharmacy
On-call pharmacies near you
Same-strength alternatives — cheapest first
Co-Arapro 300 mg / 12.5 mg (ZENITH PHARMA) contains the same active substance as Co-Irvel 300 mg / 12.5 mg (Irbesartan | hydrochlorotiazide) at the same strength, but in a different pack: Boite de 10 at 60.70 MAD, i.e. 6.07 MAD per unit against 6.07 MAD for Co-Irvel 300 mg / 12.5 mg. The public sale price is set by the Ministry of Health: it is identical in every pharmacy.
Same pack size
| Product | Manufacturer | Pack | PPV | Unit price | Difference |
|---|---|---|---|---|---|
| Co-Icard 300 mg / 12.5 mg | COOPER PHARMA | Boite de 14 | 85 MAD | 6.07 / unit | — |
Other pack sizes
| Product | Manufacturer | Pack | PPV | Unit price |
|---|---|---|---|---|
| Co-Arapro 300 mg / 12.5 mg | ZENITH PHARMA | Boite de 10 | 60.70 MAD | 6.07 / unit |
| Irphi Plus 300 mg / 12.5 mg | PHI | Boite de 10 | 60.70 MAD | 6.07 / unit |
| Irphi Plus 300 mg / 12.5 mg | PHI | Boite de 20 | 88.50 MAD | 4.43 / unit |
| Co-Irbesar Sun 300 mg / 12.5 mg | SUN PHARMACEUTICALS NORTH AFRICA S.A | Boite de 28 | 158 MAD | 5.64 / unit |
| Co-Irvel 300 mg / 12.5 mg | AFRIC-PHAR | Boite de 28 | 158 MAD | 5.64 / unit |
| Co-Vepran 300 mg / 12.5 mg | SOTHEMA | Boite de 28 | 158 MAD | 5.64 / unit |
| Coavacor 300 mg / 12.5 mg | POLYMEDIC | Boite de 30 | 158.20 MAD | 5.27 / unit |
Substituting a generic is the pharmacist's decision; for medicines listed in schedules A, B and C it still requires a prescription. Public sale prices published by the Directorate of Medicines and Pharmacy, recorded on 9/8/2026.
About Co-Irvel 300 mg / 12.5 mg
Co-Irvel 300 mg / 12.5 mg belongs to the agents acting on the renin-angiotensin system therapeutic class. In Morocco, this drug is marketed by AFRIC-PHAR and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of Co-Irvel 300 mg / 12.5 mg, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about Co-Irvel 300 mg / 12.5 mg
Answers to common questions from Moroccan patients about this drug.